STOCKHOLM, Aug. 21, 2018 /PRNewswire/ -- January 1 ? June 30, 2018
The second quarter in figures
The first half-year in figures
Important events during the quarter
Important events after the end of the period
Apr1 - June 30 |
Jan 1 - June 30 |
July 1 2017 |
Jan 1 - Dec 31 | |||
THE GROUP |
2018 |
2017 |
2018 |
2017 |
Rolling-12 |
2017 |
Net sales, SEK ths |
1 571 |
2 046 |
3 510 |
3 801 |
6 568 |
6 859 |
Gross margin, % |
58,2% |
34,2% |
51,7% |
30,6% |
46,8% |
35,4% |
Equity/Asset ratio, % |
92,0% |
87,2% |
92,0% |
87,2% |
89,9% |
90,5% |
Net indebtness, multiple |
0,09 |
0,15 |
0,09 |
0,15 |
0,11 |
0,11 |
Cash equivalents, SEK ths |
85 231 |
60 974 |
85 231 |
60 974 |
85 231 |
110 015 |
Cashflow from operating activities, SEK ths |
-10 119 |
-11 044 |
-19 801 |
-23 025 |
-40 955 |
-44 180 |
Earnings per share (before and after dilution), SEK |
-0,62 |
-1,42 |
-1,20 |
-2,82 |
-3,09 |
-5,00 |
Shareholder's equity per share, SEK |
5,76 |
8,38 |
5,76 |
8,38 |
7,80 |
13,63 |
Average number of shares, 000' |
16 618 |
8 285 |
16 618 |
8 285 |
10 576 |
8 493 |
Number of shares at closing of period, 000' |
16 618 |
8 285 |
16 618 |
8 285 |
16 618 |
16 618 |
Share price at end of period, SEK |
6,45 |
19,08 |
7,45 |
19,08 |
7,45 |
7,80 |
Number of sold electrodes, pieces |
4 304 |
5 232 |
8 438 |
9 328 |
15 814 |
16 704 |
Average number of employees |
20 |
21 |
20 |
22 |
20 |
21 |
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August 21, 2018.
This interim report has not been subject to review by the Company's auditors.
Contact person:
Michael Colérus, CFO
For more information, please contact:
Simon Grant
CEO SciBase
Phone: +46-72-887-43-99
Email: [email protected]
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and now also a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North ("SCIB"). Avanza is the certified advisor. Further information is available on www.scibase.com.
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/scibase/r/interim-report,c2596416
The following files are available for download:
These press releases may also interest you
|